je.st
news
Home
› Intersect ENT Announces FDA Submission To Seek Expanded Indication Of PROPEL Mini Steroid Releasing Implant To Treat Patients With Frontal Sinus Disease
Intersect ENT Announces FDA Submission To Seek Expanded Indication Of PROPEL Mini Steroid Releasing Implant To Treat Patients With Frontal Sinus Disease
2015-09-30 08:48:02| drugdiscoveryonline News Articles
Intersect ENT, Inc., a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, recently announced that the company has submitted a supplemental premarket approval (PMA-s) submission to the U.S
Tags: mini
expanded
disease
patients
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||